Home » Stocks » PSTI

Pluristem Therapeutics, Inc. (PSTI)

Stock Price: $3.54 USD -0.31 (-8.05%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $3.59 +0.05 (1.41%) May 13, 7:55 PM
Market Cap 112.36M
Revenue (ttm) n/a
Net Income (ttm) -43.43M
Shares Out 31.74M
EPS (ttm) -1.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $3.54
Previous Close $3.85
Change ($) -0.31
Change (%) -8.05%
Day's Open 3.91
Day's Range 3.50 - 3.92
Day's Volume 362,363
52-Week Range 3.50 - 12.15

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Pluristem Therapeutics Inc (NASDAQ: PSTI) has reported positive topline results from Phase 1 study evaluating intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery follo...

2 weeks ago - Benzinga

HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic prod...

3 months ago - GlobeNewsWire

HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic prod...

4 months ago - GlobeNewsWire

HAIFA, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic pr...

5 months ago - GlobeNewsWire

Pluristem's CLI Phase III trial interim results should be published soon. Results are critical and might define the fate of the company.

5 months ago - Seeking Alpha

HAIFA, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic pr...

5 months ago - GlobeNewsWire

HAIFA, Israel, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, toda...

6 months ago - GlobeNewsWire

Two new sample breakout stocks for Week 43 with better than 10% short-term upside potential. Now up an average +241.2% YTD.

Other stocks mentioned: CAT, CSCO, ECOM, HON, INTC, JNJ, MCD ...
6 months ago - Seeking Alpha

Investors need to pay close attention to Pluristem Therapeutics (PSTI) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Reports internal efficacy and safety data from first cohort Reports internal efficacy and safety data from first cohort

7 months ago - GlobeNewsWire

HAIFA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic pr...

7 months ago - GlobeNewsWire

HAIFA, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products...

7 months ago - GlobeNewsWire

HAIFA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeut...

8 months ago - GlobeNewsWire

Pluristem (PSTI) completes enrollment in the phase I study in patients with complete hematopoietic recovery following hematopoietic cell transplantation in the United States and Israel.

8 months ago - Zacks Investment Research

Top line efficacy results expected Q1 2021 Top line efficacy results expected Q1 2021

8 months ago - GlobeNewsWire

HAIFA, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...

9 months ago - GlobeNewsWire

HAIFA, Israel, June 11, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeut...

11 months ago - GlobeNewsWire

HAIFA, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...

11 months ago - GlobeNewsWire

Is (PSTI) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Pluristem Therapeutics: The Search For An ARDS Treatment, And Whether Its Growth Will Continue

11 months ago - Seeking Alpha

Is (PSTI) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Update is provided in advance of the company’s recruitment of first patient for its phase II Covid-19 study Update is provided in advance of the company’s recruitment of first patient for its phase II C...

11 months ago - GlobeNewsWire

HAIFA, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.  (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeuti...

1 year ago - GlobeNewsWire

HAIFA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.  (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic ...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Pluristem Therapeutics Inc. (PSTI).

1 year ago - Zacks Investment Research

Does Pluristem (PSTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

• Elaborating on agreement terms and tranches schedule • Provides update on cash position and clinical program

1 year ago - GlobeNewsWire

Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.

Other stocks mentioned: ATHX, MESO
1 year ago - The Motley Fool

The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.

1 year ago - The Motley Fool

EXPECTED ONLINE SIGNING CEREMONY ON APRIL 30, 2020 EXPECTED ONLINE SIGNING CEREMONY ON APRIL 30, 2020

1 year ago - GlobeNewsWire

Orgenesis Acquiring Tamir, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: ORGS, TDOC
1 year ago - Seeking Alpha

Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.

1 year ago - Zacks Investment Research

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Other stocks mentioned: ATHX, GILD, JNJ, MESO, PFE, REGN
1 year ago - Zacks Investment Research

HAIFA, Israel, April 13, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeuti...

1 year ago - GlobeNewsWire

Investors need to pay close attention to Pluristem (PSTI) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Pluristem Therapeutics (NASDAQ: PSTI) shares are trading higher on Tuesday, after the company reported preliminary data from its coronavirus compassionate use program, treating seven patients with acute...

1 year ago - Benzinga

HAIFA, Israel, April 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeu...

1 year ago - GlobeNewsWire

HAIFA, Israel, March 30, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeu...

1 year ago - GlobeNewsWire

HAIFA, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, to...

1 year ago - GlobeNewsWire

HAIFA, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- HAIFA, Israel, March 12, 20 20 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a p...

1 year ago - GlobeNewsWire

HAIFA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel cell therapy product...

1 year ago - GlobeNewsWire

HAIFA, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...

1 year ago - GlobeNewsWire

Patients unsuitable for revascularization surgery currently have no alternative treatments, leading to high risk of leg amputation and death; PLX-PAD may become the first drug approved to treat CLI Pati...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor Pluristem Therapeutics.

1 year ago - Zacks Investment Research

Multinational study in the U.S., Israel and Europe targeting to be the first product candidate supporting muscle regeneration after significant trauma such as hip fracture Multinational study in the U.S...

1 year ago - GlobeNewsWire

HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...

1 year ago - GlobeNewsWire

Pluristem Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

HAIFA, Israel, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...

1 year ago - GlobeNewsWire

Data readout from second cohort of hematological study will be presented Call scheduled for Monday, September 16 at 10:00am ET Data readout from second cohort of hematological study will be presented Ca...

1 year ago - GlobeNewsWire

About PSTI

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) ... [Read more...]

Industry
Biotechnology
Founded
2001
CEO
Yaky Yanay
Employees
146
Stock Exchange
NASDAQ
Ticker Symbol
PSTI
Full Company Profile

Financial Performance

In 2020, PSTI's revenue was $23,000, a decrease of -57.41% compared to the previous year's $54,000. Losses were -$29.15 million, -17.43% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for PSTI stock is "Buy." The 12-month stock price forecast is 9.08, which is an increase of 156.50% from the latest price.

Price Target
$9.08
(156.50% upside)
Analyst Consensus: Buy